Approach Bias Modification for the Treatment of Cannabis Use Disorder

Status Completed

Clinical Trial Summary

Effective and durable treatments for cannabis use disorder remain elusive. Given the increasing prevalence rates of cannabis use and CUD nationwide, investigation of novel treatments is warranted. Implicit cognitive processing is an emerging, and potentially critical therapeutic target. Cognitive models of addiction posit an override of explicit control-related cognitive processes by implicit reward-driven processes resulting from chronic drug exposure. One form of implicit cognitive processing is approach bias, or, the automatic tendency to approach rather than avoid drug cues, which has been identified for alcohol, nicotine, opioids, and cannabis. Cannabis approach bias predicts increased cannabis use, dependence severity, and cannabis-related problems among heavy cannabis users. Approach bias modification (ABM) is a novel treatment approach that seeks to reduce approach bias by attenuating the incentive-salience of drug cues, and subsequently, drug cue reactivity and drug use. ABM has been shown to reduce relapse rates in alcohol dependent adults by 10-13% at one-year follow-up, and dependence severity in nicotine dependent adults. Our pilot data suggests that ABM may also reduce cannabis craving and that gender may moderate the effect of ABM on cannabis sessions per day in non-treatment seeking adults with CUD. A recent fMRI study with alcohol-dependent adults found decreased mesolimbic activation in participants who received ABM compared to sham-control participants. ABM appears to target implicit reward-driven processes, and could be an effective adjunct to traditional psychosocial and/or future pharmacological interventions that target explicit control-related processes. Building on our promising feasibility data, the proposed K23 research study will examine the effects of ABM on cue-reactivity and cannabis outcomes in a four-session randomized, double-blind, sham-controlled pilot treatment trial. One-hundred and six (106) treatment-seeking adults with moderate to severe CUD will be randomized to receive either MET/CBT plus ABM or Motivational Enhancement Therapy/Cognitive Behavioral Therapy(MET/CBT) plus sham-ABM. An equal number of men and women will be recruited and randomization will be stratified by gender. ABM sessions will occur following each of the three weekly MET/CBT therapy sessions. Primary outcomes will include cannabis cue-reactivity and cannabis use.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03629990
Study type	Interventional
Source	Medical University of South Carolina
Contact
Status	Completed
Phase	N/A
Start date	January 16, 2019
Completion date	October 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05726617` - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders	N/A
Not yet recruiting	`NCT04139668` - Vivitrol Treatment for Cannabis Use Disorder	Phase 2
Completed	`NCT01656707` - Adaptive Treatment for Adolescent Cannabis Use Disorders	N/A
Completed	`NCT03204305` - Brain Imaging of Cannabinoid Receptors	Early Phase 1
Completed	`NCT05005013` - A Teleheath tDCS Approach to Decrease Cannabis Use	N/A
Recruiting	`NCT05292547` - Repetitive Transcranial Magnetic Stimulation to People With Cannabis Use Disorder (SToP-C-rTMS x CUD)	N/A
Completed	`NCT02932215` - Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder	Phase 1
Completed	`NCT03430050` - Progesterone for Cannabis Withdrawal	Early Phase 1
Withdrawn	`NCT03629106` - Effects of Cannabis Abstinence on Symptomology and Cognition in Bipolar Disorder	N/A
Completed	`NCT03334721` - Gabapentin for Bipolar & Cannabis Use Disorders	Phase 2
Recruiting	`NCT04721353` - Reducing Cannabis Overuse With Prazosin	Phase 4
Completed	`NCT03718520` - The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
Completed	`NCT03624933` - Effects of Cannabis Abstinence on Symptoms and Cognition in Depression	N/A
Recruiting	`NCT05836207` - Rewards for Cannabis Abstinence-study	N/A
Not yet recruiting	`NCT06114212` - Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder	N/A
Recruiting	`NCT05855668` - Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment	N/A
Recruiting	`NCT04517474` - Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use.	N/A
Recruiting	`NCT05885542` - SCORE Emerging Adult Cannabis Use & Stress	Phase 1/Phase 2
Not yet recruiting	`NCT06085222` - Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users	Phase 1
Completed	`NCT03056482` - Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.